CPC C07D 471/10 (2013.01) [A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07D 487/10 (2013.01); C07D 491/20 (2013.01); C07D 519/00 (2013.01)] | 10 Claims |
1. A method for treating a disease, condition or disorder mediated by the inhibition of acetyl-CoA carboxylase enzymes in a human, the method comprising the step of administering to the human in need of such treatment a therapeutically effective amount of a compound of structure:
or a pharmaceutically acceptable salt thereof, wherein the disease, condition or disorder is selected from the group consisting of Type I diabetes, Type II diabetes and diabetes-related diseases, nonalcoholic fatty liver disease (NAFLD), hepatic insulin resistance, hyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, obesity, obesity-related disorders, dyslipidemia, hypertension, hyperinsulinemia, insulin resistance syndrome, atherosclerosis, coronary heart disease, coronary artery disease, heart failure, stroke, peripheral vascular disease, nephropathy, hypertension, neuropathy, and retinopathy.
|